Granules India's paracetamol facility passes USFDA inspection

Tags: Companies
Drug firm Granules India's paracetamol manufacturing facility at Bonthapally in Andhra Pradesh has passed an inspection by the US health regulator.

The company's paracetamol facility has successfully passed a United States Food and Drug Administration (USFDA) inspection without any '483 observations', Granules India said in a filing to the BSE.

"The facility has the world's largest single active pharmaceutical ingredient (API) production line by volume," it added.

An FDA Form 483 is issued to the firm's management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and other related acts.

The company's four API facilities have passed the USFDA inspections in the past 12 months, Granules India said.

Hyderabad-based Granules India has facilities for APIs, pharmaceutical formulation intermediates (PFIs) and finished dosages, serving customers in over 60 countries.

Shares of Granules India were trading at Rs 401.75 per scrip in the afternoon trade today, up 1.40 per cent from its previous close, on the BSE.


  • Banking security breach reveals how vulnerable the system is

    Fear has gripped millions of Indians whose bank accounts have been compromised due to a massive security breach in the payments ecosystem linked with


Stay informed on our latest news!


Urs Schoettli

Just how useful are summits?

In the age of globalisation international summits play an increasingly ...

Zehra Naqvi

Of absolute truth & relative perception

Is there such a thing as absolute truth? Look around ...

Shona Adhikari

When art meets the artful

This week’s art news focuses on vastly different themes and ...